iLite® EGFR (-) Target
BM5036
A negative control cell line for EGFR-targeted bioassays, this iLite® target is used in assay specificity evaluation.
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
Product Overview
iLite® ADCC Target EGFR (-) Assay Ready Cells are based on the human embryonic kidney cell line, HEK293, and have been genetically engineered to be depleted of EGRF expression.
These cells are optimized to be used as negative control together with iLite® ADCC Effector (V) Assay Ready Cells and iLite® ADCC Target EGFR (+) Assay Ready Cells for measuring the ADCC activity of anti-EGFR antibodies.
FOR RESEARCH USE ONLY
How it works
Principle of iLite® ADCC Bioassays
Our two-cell ADCC bioassays consist of target cells expressing the antigen under study and effector cells closely resembling the natural FcγRIIIa (CD16) signal transduction pathway. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.
What's in the box?
>250 µL of Assay Ready Cells suspended in cryoprotective medium.
Specifications
| Product code | BM5036 |
| Assay target | ADCC EGFR |
| Size | 1 vial corresponding to one 96 well plate |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
Documents
Downloads
Designing Optimal Bioassays for Measuring ADCC & ADCP Activity
Read post
Quantification of ADCP Activity of Therapeutic Antibodies Using Engineered Effector Cells and Target...
Read post
A Novel Method for ADCC Activity Quantification using Engineered Effector Cells
Read post
Navigating the Complexities of Cell-based Assays in GMP QC Testing: The Journey to Robust Assays
Read post
The Value of Assay-Ready Cells in Providing Biologically Relevant Data for Robust Therapeutic Develo...
Read post
How Biosimilars Are Expanding Options for Patient Care
Read post
Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeuti...
Read post
The Future of Drug Development for Complex Pathologies: Versatile Cell-based Assays and Customizable...
Read post
Webinar - Advancements in GMP QC Testing: A Comprehensive Guide to Cell-Based Assays
Read post
